Inspire Investing LLC Has $5.88 Million Position in United Therapeutics Corporation $UTHR

Inspire Investing LLC lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 64.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,064 shares of the biotechnology company’s stock after acquiring an additional 4,739 shares during the period. Inspire Investing LLC’s holdings in United Therapeutics were worth $5,878,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Torren Management LLC acquired a new position in United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new position in United Therapeutics during the fourth quarter worth $31,000. Wilmington Savings Fund Society FSB raised its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in United Therapeutics during the fourth quarter worth $48,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $549.17, for a total value of $5,491,700.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,366,132.92. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $549.15, for a total transaction of $5,216,925.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,247,713.95. The trade was a 19.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 636,168 shares of company stock worth $359,249,237 in the last quarter. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $551.47 on Thursday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm has a market cap of $23.41 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 1.79 and a beta of 0.57. The company has a fifty day moving average price of $565.95 and a 200-day moving average price of $522.96.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the company earned $6.63 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on UTHR. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America upped their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Finally, HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.